{"transactions":[{"id":4618154,"issuer":{"id":5669,"kind":"organization","name":"Mobia Medical, Inc.","symbol":"MOBI"},"owners":[{"id":48321,"kind":"person","name":"Leavitt Chase C.","position":1,"cik":"0001777467","reported_name":"Leavitt Chase C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Common Stock","published_at":"2026-09-15T20:34:26.000Z","date":"2026-09-11","kind":"purchase","planned":false,"acquired":true,"shares":2000,"price":10.3,"value":20600.0,"ownership":{"direct":true},"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001193125-26-391998","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1777467/000119312526391998/ownership.xml","form_type":"4"}},{"id":784697,"issuer":{"id":5669,"kind":"organization","name":"Mobia Medical, Inc.","symbol":"MOBI"},"owners":[{"id":48321,"kind":"person","name":"Leavitt Chase C.","position":1,"cik":"0001777467","reported_name":"Leavitt Chase C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option","published_at":"2026-05-12T01:36:38.000Z","date":"2026-05-07","kind":"grant","planned":false,"acquired":true,"shares":175760,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest as to 25% of the underlying shares on May 7, 2027, and will vest thereafter in 36 substantially equal monthly installments."}],"balance_after":175760,"derivative":{"exercise_price":15,"expiration_date":"2036-05-07","underlying":"Common Stock","underlying_shares":175760},"source":{"system":"sec-edgar","filing":"0001628280-26-033808","document":"wk-form4_1778549795.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1489993/000162828026033808/wk-form4_1778549795.xml","form_type":"4"}},{"id":784696,"issuer":{"id":5669,"kind":"organization","name":"Mobia Medical, Inc.","symbol":"MOBI"},"owners":[{"id":48321,"kind":"person","name":"Leavitt Chase C.","position":1,"cik":"0001777467","reported_name":"Leavitt Chase C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-05-12T01:36:38.000Z","date":"2026-05-11","kind":"purchase","planned":false,"acquired":true,"shares":3000,"price":15,"value":45000.0,"ownership":{"direct":true},"balance_after":3000,"source":{"system":"sec-edgar","filing":"0001628280-26-033808","document":"wk-form4_1778549795.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1489993/000162828026033808/wk-form4_1778549795.xml","form_type":"4"}},{"id":1640758,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":48321,"kind":"person","name":"Leavitt Chase C.","position":1,"cik":"0001777467","reported_name":"Leavitt Chase C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel/Secretary"}}],"security":"Stock Option","published_at":"2024-02-15T18:00:23.000Z","date":"2024-02-14","kind":"grant","planned":false,"acquired":true,"shares":14200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the stock option vest on first anniversary of the date of grant, and the remaining shares subject to the option vest in 36 equal monthly installments, subject to the recipient's continued employment or service with the Issuer on each such date."}],"balance_after":14200,"derivative":{"exercise_price":9.18,"expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":14200},"source":{"system":"sec-edgar","filing":"0001209191-24-003412","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919124003412/doc4.xml","form_type":"4"}},{"id":1685353,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":48321,"kind":"person","name":"Leavitt Chase C.","position":1,"cik":"0001777467","reported_name":"Leavitt Chase C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel/Secretary"}}],"security":"Common Stock","published_at":"2024-01-05T16:00:20.000Z","date":"2024-01-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":11838,"price":0.4961,"value":5872.8318,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld by the Issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units."}],"balance_after":84758,"source":{"system":"sec-edgar","filing":"0001209191-24-000971","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919124000971/doc4.xml","form_type":"4"}},{"id":1765095,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":48321,"kind":"person","name":"Leavitt Chase C.","position":1,"cik":"0001777467","reported_name":"Leavitt Chase C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel/Secretary"}}],"security":"Stock Option","published_at":"2023-10-04T17:01:49.000Z","date":"2023-10-02","kind":"grant","planned":false,"acquired":true,"shares":235000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"25% of the Option Shares vested on April 12, 2022, and the remaining Option Shares vest in 36 equal monthly installments thereafter, subject to the recipient's continued service. The option may not be exercised if recipient's employment or service terminates prior to October 2, 2024 other than as a result of a Qualifying Termination. All of the Option Shares vest and become exercisable in the event of a Change in Control."}],"balance_after":235000,"derivative":{"exercise_price":0.31,"expiration_date":"2033-10-02","underlying":"Common Stock","underlying_shares":235000},"source":{"system":"sec-edgar","filing":"0001209191-23-052023","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919123052023/doc4.xml","form_type":"4"}},{"id":1765094,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":48321,"kind":"person","name":"Leavitt Chase C.","position":1,"cik":"0001777467","reported_name":"Leavitt Chase C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel/Secretary"}}],"security":"Stock Option","published_at":"2023-10-04T17:01:49.000Z","date":"2023-10-02","kind":"grant","planned":false,"acquired":true,"shares":210000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The exercise price of the option is $0.31 per share, representing the fair market value per share of the common stock on the grant date; provided that the exercise price will be increased to the original exercise price before repricing if, prior to April 2, 2025: (i) recipient's employment or service terminates, other than due to a Qualifying Termination; or (ii) the option is exercised."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On October 2, 2023, the Issuer repriced the option. Except as described further in footnotes 6 and 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the Option Shares vest on February 21, 2024, and the remaining Option Shares vest in 36 equal monthly installments thereafter, subject to the recipient's continued service."}],"balance_after":210000,"derivative":{"exercise_price":0.31,"expiration_date":"2033-02-21","underlying":"Common Stock","underlying_shares":210000},"source":{"system":"sec-edgar","filing":"0001209191-23-052023","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919123052023/doc4.xml","form_type":"4"}},{"id":1765093,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":48321,"kind":"person","name":"Leavitt Chase C.","position":1,"cik":"0001777467","reported_name":"Leavitt Chase C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel/Secretary"}}],"security":"Stock Option","published_at":"2023-10-04T17:01:49.000Z","date":"2023-10-02","kind":"grant","planned":false,"acquired":true,"shares":28750,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The exercise price of the option is $0.31 per share, representing the fair market value per share of the common stock on the grant date; provided that the exercise price will be increased to the original exercise price before repricing if, prior to April 2, 2025: (i) recipient's employment or service terminates, other than due to a Qualifying Termination; or (ii) the option is exercised."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On October 2, 2023, the Issuer repriced the option. Except as described further in footnotes 6 and 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"50% of the Option Shares vested on July 3, 2023, and 50% of the Option Shares vest on January 3, 2024, subject to the recipient's continued service. All of the Option Shares vest in the event of a Change in Control (as defined in the Issuer's 2019 Incentive Award Plan)."}],"balance_after":28750,"derivative":{"exercise_price":0.31,"expiration_date":"2032-07-28","underlying":"Common Stock","underlying_shares":28750},"source":{"system":"sec-edgar","filing":"0001209191-23-052023","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919123052023/doc4.xml","form_type":"4"}},{"id":1765092,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":48321,"kind":"person","name":"Leavitt Chase C.","position":1,"cik":"0001777467","reported_name":"Leavitt Chase C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel/Secretary"}}],"security":"Stock Option","published_at":"2023-10-04T17:01:49.000Z","date":"2023-10-02","kind":"grant","planned":false,"acquired":true,"shares":55519,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The exercise price of the option is $0.31 per share, representing the fair market value per share of the common stock on the grant date; provided that the exercise price will be increased to the original exercise price before repricing if, prior to April 2, 2025: (i) recipient's employment or service terminates, other than due to a Qualifying Termination; or (ii) the option is exercised."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On October 2, 2023, the Issuer repriced the option. Except as described further in footnotes 6 and 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the Option Shares vested on January 20, 2023, and the remaining Option Shares vest in 36 equal monthly installments thereafter, subject to the recipient's continued service."}],"balance_after":55519,"derivative":{"exercise_price":0.31,"expiration_date":"2032-01-20","underlying":"Common Stock","underlying_shares":55519},"source":{"system":"sec-edgar","filing":"0001209191-23-052023","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919123052023/doc4.xml","form_type":"4"}},{"id":1765091,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":48321,"kind":"person","name":"Leavitt Chase C.","position":1,"cik":"0001777467","reported_name":"Leavitt Chase C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel/Secretary"}}],"security":"Stock Option","published_at":"2023-10-04T17:01:49.000Z","date":"2023-10-02","kind":"grant","planned":false,"acquired":true,"shares":65000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The exercise price of the option is $0.31 per share, representing the fair market value per share of the common stock on the grant date; provided that the exercise price will be increased to the original exercise price before repricing if, prior to October 2, 2024: (i) recipient's employment or service terminates, other than due to death, disability, or circumstances giving rise to severance under the recipient's employment agreement (a \"Qualifying Termination\"); or (ii) the option is exercised."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On October 2, 2023, the Issuer repriced the option. Except as described further in footnotes 6 and 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option (\"Option Shares\") vested on April 12, 2022, and the remaining Option Shares vest in 36 equal monthly installments thereafter, subject to the recipient's continued service."}],"balance_after":65000,"derivative":{"exercise_price":0.31,"expiration_date":"2031-04-29","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001209191-23-052023","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919123052023/doc4.xml","form_type":"4"}},{"id":1765090,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":48321,"kind":"person","name":"Leavitt Chase C.","position":1,"cik":"0001777467","reported_name":"Leavitt Chase C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel/Secretary"}}],"security":"Stock Option","published_at":"2023-10-04T17:01:49.000Z","date":"2023-10-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":210000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On October 2, 2023, the Issuer repriced the option. Except as described further in footnotes 6 and 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the Option Shares vest on February 21, 2024, and the remaining Option Shares vest in 36 equal monthly installments thereafter, subject to the recipient's continued service."}],"balance_after":0,"derivative":{"exercise_price":0.96,"expiration_date":"2033-02-21","underlying":"Common Stock","underlying_shares":210000},"source":{"system":"sec-edgar","filing":"0001209191-23-052023","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919123052023/doc4.xml","form_type":"4"}},{"id":1765089,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":48321,"kind":"person","name":"Leavitt Chase C.","position":1,"cik":"0001777467","reported_name":"Leavitt Chase C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel/Secretary"}}],"security":"Stock Option","published_at":"2023-10-04T17:01:49.000Z","date":"2023-10-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":28750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On October 2, 2023, the Issuer repriced the option. Except as described further in footnotes 6 and 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"50% of the Option Shares vested on July 3, 2023, and 50% of the Option Shares vest on January 3, 2024, subject to the recipient's continued service. All of the Option Shares vest in the event of a Change in Control (as defined in the Issuer's 2019 Incentive Award Plan)."}],"balance_after":0,"derivative":{"exercise_price":1.04,"expiration_date":"2032-07-28","underlying":"Common Stock","underlying_shares":28750},"source":{"system":"sec-edgar","filing":"0001209191-23-052023","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919123052023/doc4.xml","form_type":"4"}},{"id":1765088,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":48321,"kind":"person","name":"Leavitt Chase C.","position":1,"cik":"0001777467","reported_name":"Leavitt Chase C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel/Secretary"}}],"security":"Stock Option","published_at":"2023-10-04T17:01:49.000Z","date":"2023-10-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":55519,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On October 2, 2023, the Issuer repriced the option. Except as described further in footnotes 6 and 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the Option Shares vested on January 20, 2023, and the remaining Option Shares vest in 36 equal monthly installments thereafter, subject to the recipient's continued service."}],"balance_after":0,"derivative":{"exercise_price":1.94,"expiration_date":"2032-01-20","underlying":"Common Stock","underlying_shares":55519},"source":{"system":"sec-edgar","filing":"0001209191-23-052023","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919123052023/doc4.xml","form_type":"4"}},{"id":1765087,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":48321,"kind":"person","name":"Leavitt Chase C.","position":1,"cik":"0001777467","reported_name":"Leavitt Chase C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel/Secretary"}}],"security":"Stock Option","published_at":"2023-10-04T17:01:49.000Z","date":"2023-10-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":65000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On October 2, 2023, the Issuer repriced the option. Except as described further in footnotes 6 and 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option (\"Option Shares\") vested on April 12, 2022, and the remaining Option Shares vest in 36 equal monthly installments thereafter, subject to the recipient's continued service."}],"balance_after":0,"derivative":{"exercise_price":6.46,"expiration_date":"2031-04-29","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001209191-23-052023","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919123052023/doc4.xml","form_type":"4"}},{"id":1835596,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":48321,"kind":"person","name":"Leavitt Chase C.","position":1,"cik":"0001777467","reported_name":"Leavitt Chase C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel/Secretary"}}],"security":"Common Stock","published_at":"2023-07-05T18:59:18.000Z","date":"2023-07-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":10305,"price":0.36,"value":3709.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld by the Issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units."}],"balance_after":96596,"source":{"system":"sec-edgar","filing":"0001209191-23-041318","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919123041318/doc4.xml","form_type":"4"}},{"id":1919458,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":48321,"kind":"person","name":"Leavitt Chase C.","position":1,"cik":"0001777467","reported_name":"Leavitt Chase C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel/Secretary"}}],"security":"Common Stock","published_at":"2023-04-14T06:00:16.000Z","date":"2023-04-13","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":0.29,"value":2900.0,"ownership":{"direct":true},"balance_after":106901,"source":{"system":"sec-edgar","filing":"0001209191-23-024264","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919123024264/doc4.xml","form_type":"4"}},{"id":1919457,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":48321,"kind":"person","name":"Leavitt Chase C.","position":1,"cik":"0001777467","reported_name":"Leavitt Chase C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel/Secretary"}}],"security":"Common Stock","published_at":"2023-04-14T06:00:16.000Z","date":"2023-04-12","kind":"purchase","planned":false,"acquired":true,"shares":15000,"price":0.29,"value":4350.0,"ownership":{"direct":true},"balance_after":96901,"source":{"system":"sec-edgar","filing":"0001209191-23-024264","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919123024264/doc4.xml","form_type":"4"}},{"id":1995619,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":48321,"kind":"person","name":"Leavitt Chase C.","position":1,"cik":"0001777467","reported_name":"Leavitt Chase C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel/Secretary"}}],"security":"Stock Option","published_at":"2023-02-23T20:01:14.000Z","date":"2023-02-21","kind":"grant","acquired":true,"shares":210000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the stock option vest on first anniversary of the date of grant, and the remaining shares subject to the option vest in 36 equal monthly installments, subject to the recipient's continued employment or service with the Issuer on each such date."}],"balance_after":210000,"derivative":{"exercise_price":0.96,"expiration_date":"2033-02-21","underlying":"Common Stock","underlying_shares":210000},"source":{"system":"sec-edgar","filing":"0001209191-23-012401","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919123012401/doc4.xml","form_type":"4"}},{"id":2062364,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":48321,"kind":"person","name":"Leavitt Chase C.","position":1,"cik":"0001777467","reported_name":"Leavitt Chase C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel/Secretary"}}],"security":"Common Stock","published_at":"2023-01-05T18:00:38.000Z","date":"2023-01-03","kind":"tax_withholding","acquired":false,"shares":6091,"price":1.02,"value":6212.82,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld by the Issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units."}],"balance_after":81901,"source":{"system":"sec-edgar","filing":"0001209191-23-002031","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919123002031/doc4.xml","form_type":"4"}},{"id":2198949,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":48321,"kind":"person","name":"Leavitt Chase C.","position":1,"cik":"0001777467","reported_name":"Leavitt Chase C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel/Secretary"}}],"security":"Stock Option","published_at":"2022-08-01T18:22:39.000Z","date":"2022-07-28","kind":"grant","acquired":true,"shares":28750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One half of the shares subject to the stock options vest on July 3, 2023 and one half of the shares subject to the stock options vest on January 3, 2024, subject to the Reporting Person's continued employment or service with the Issuer on each such date. All of the shares subject to the stock options vest in the event of a Change in Control (as defined in the Issuer's 2019 Incentive Award Plan)."}],"balance_after":28750,"derivative":{"exercise_price":1.04,"expiration_date":"2032-07-28","underlying":"Common Stock","underlying_shares":28750},"source":{"system":"sec-edgar","filing":"0001209191-22-043739","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919122043739/doc4.xml","form_type":"4"}},{"id":2198948,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":48321,"kind":"person","name":"Leavitt Chase C.","position":1,"cik":"0001777467","reported_name":"Leavitt Chase C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel/Secretary"}}],"security":"Common Stock","published_at":"2022-08-01T18:22:39.000Z","date":"2022-07-28","kind":"grant","acquired":true,"shares":43125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of restricted stock units (RSUs). Each RSU represents the right to receive one share of the Issuer's common stock upon vesting. One half of the RSUs vest on July 3, 2023, and one half of the RSUs vest on January 3, 2024, subject to the Reporting Person's continued employment or service with the Issuer on each such date. All of the RSUs vest in the event of a Change in Control (as defined in the Issuer's 2019 Incentive Award Plan)."}],"balance_after":87992,"source":{"system":"sec-edgar","filing":"0001209191-22-043739","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919122043739/doc4.xml","form_type":"4"}},{"id":2420978,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":48321,"kind":"person","name":"Leavitt Chase C.","position":1,"cik":"0001777467","reported_name":"Leavitt Chase C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel/Secretary"}}],"security":"Common Stock","published_at":"2022-01-31T16:00:18.000Z","date":"2022-01-28","kind":"purchase","acquired":true,"shares":5000,"price":1.63,"value":8150.0,"ownership":{"direct":true},"balance_after":44867,"source":{"system":"sec-edgar","filing":"0001209191-22-005558","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919122005558/doc4.xml","form_type":"4"}},{"id":2420977,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":48321,"kind":"person","name":"Leavitt Chase C.","position":1,"cik":"0001777467","reported_name":"Leavitt Chase C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel/Secretary"}}],"security":"Common Stock","published_at":"2022-01-31T16:00:18.000Z","date":"2022-01-27","kind":"purchase","acquired":true,"shares":8500,"price":1.78,"value":15130.0,"ownership":{"direct":true},"balance_after":39867,"source":{"system":"sec-edgar","filing":"0001209191-22-005558","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919122005558/doc4.xml","form_type":"4"}},{"id":2427599,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":48321,"kind":"person","name":"Leavitt Chase C.","position":1,"cik":"0001777467","reported_name":"Leavitt Chase C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel/Secretary"}}],"security":"Stock Option","published_at":"2022-01-24T16:00:19.000Z","date":"2022-01-20","kind":"grant","acquired":true,"shares":55519,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth of the shares subject to the stock options shall vest on first anniversary of the date of grant, and the remaining shares subject to the option shall vest in 36 equal monthly installments over the three-year period thereafter, subject to the Reporting Person's continued employment or service with the Issuer on each such date."}],"balance_after":55519,"derivative":{"exercise_price":1.94,"expiration_date":"2032-01-20","underlying":"Common Stock","underlying_shares":55519},"source":{"system":"sec-edgar","filing":"0001209191-22-004583","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919122004583/doc4.xml","form_type":"4"}},{"id":2443360,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":48321,"kind":"person","name":"Leavitt Chase C.","position":1,"cik":"0001777467","reported_name":"Leavitt Chase C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel/Secretary"}}],"security":"Common Stock","published_at":"2022-01-05T19:00:25.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":29867,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of restricted stock units (RSUs). Each RSU represents the right to receive one share of the Issuer's common stock upon vesting. One half of the RSUs vest on January 3, 2023, one quarter of the RSUs vest on July 3, 2023, and one quarter of the RSUs vest on January 3, 2024, subject to the Reporting Person's continued employment or service with the Issuer on each such date. All of the RSUs vest in the event of a Change in Control (as defined in the Issuer's 2019 Incentive Award Plan)."}],"balance_after":31367,"source":{"system":"sec-edgar","filing":"0001209191-22-001973","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919122001973/doc4.xml","form_type":"4"}},{"id":2668024,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":48321,"kind":"person","name":"Leavitt Chase C.","position":1,"cik":"0001777467","reported_name":"Leavitt Chase C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel/Secretary"}}],"security":"Common Stock","published_at":"2021-06-15T18:00:30.000Z","date":"2021-06-11","kind":"purchase","acquired":true,"shares":1500,"price":5.45,"value":8175.0,"ownership":{"direct":true},"balance_after":1500,"source":{"system":"sec-edgar","filing":"0001209191-21-040701","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000120919121040701/doc4.xml","form_type":"4"}},{"id":2784202,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":48321,"kind":"person","name":"Leavitt Chase C.","position":1,"cik":"0001777467","reported_name":"Leavitt Chase C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel/Secretary"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-03-17T21:00:44.000Z","date":"2021-03-15","kind":"grant","acquired":true,"shares":699100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One quarter of the options shall vest on March 15, 2022 and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment."}],"balance_after":699100,"derivative":{"exercise_price":2.43,"expiration_date":"2031-03-15","underlying":"Common Shares","underlying_shares":699100},"source":{"system":"sec-edgar","filing":"0001493152-21-006271","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315221006271/ownership.xml","form_type":"4"}},{"id":3201267,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":48321,"kind":"person","name":"Leavitt Chase C.","position":1,"cik":"0001777467","reported_name":"Leavitt Chase C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel/Secretary"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2020-03-19T21:00:18.000Z","date":"2020-03-17","kind":"grant","acquired":true,"shares":616700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One quarter of the options shall vest on March 17, 2021 and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment."}],"balance_after":616700,"derivative":{"exercise_price":0.6919,"expiration_date":"2030-03-17","underlying":"Common Shares","underlying_shares":616700},"source":{"system":"sec-edgar","filing":"0001493152-20-004351","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000149315220004351/ownership.xml","form_type":"4"}},{"id":3438004,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":48321,"kind":"person","name":"Leavitt Chase C.","position":1,"cik":"0001777467","reported_name":"Leavitt Chase C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel/Secretary"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-08-15T12:42:28.000Z","date":"2019-07-31","kind":"grant","acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One quarter of the options shall vest on May 20, 2020 and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment."}],"balance_after":125000,"derivative":{"exercise_price":1.1,"expiration_date":"2029-07-30","underlying":"Common Shares","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001209191-19-046031","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/876343/000120919119046031/doc4.xml","form_type":"4"}},{"id":3438003,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":48321,"kind":"person","name":"Leavitt Chase C.","position":1,"cik":"0001777467","reported_name":"Leavitt Chase C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel/Secretary"}}],"security":"Common Shares","published_at":"2019-08-15T12:42:28.000Z","date":"2019-08-13","kind":"purchase","acquired":true,"shares":5000,"price":1.02,"value":5100.0,"ownership":{"direct":true},"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001209191-19-046031","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000120919119046031/doc4.xml","form_type":"4"}},{"id":3516087,"issuer":{"id":6045,"kind":"organization","name":"Lineage Cell Therapeutics, Inc."},"owners":[{"id":48321,"kind":"person","name":"Leavitt Chase C.","position":1,"cik":"0001777467","reported_name":"Leavitt Chase C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel/Secretary"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-05-22T20:31:22.000Z","date":"2019-05-20","kind":"grant","acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One quarter of the options shall vest on May 20, 2020 and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment."}],"balance_after":300000,"derivative":{"exercise_price":1.13,"expiration_date":"2029-05-19","underlying":"Common Shares","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001209191-19-032073","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/876343/000120919119032073/doc4.xml","form_type":"4"}}]}